Showing results (51-60 of 111) with videos related to
Sort By:
Pageof 12
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|May 6, 2021
[Relationship between Dose Discontinuation or Dose Reduction for Safety Reasons in Clinical Trials and Lower-dose Prescriptions in the Post-marketing Setting]Akiko Ogata, Mamoru NarukawaCancer Control : Journal of the Moffitt Cancer Center|April 6, 2024
A Systematic Review of Treatment-Related Adverse Events for Combination Therapy of Multiple Tyrosine Kinase Inhibitor and Immune Checkpoint InhibitorTakashi Sawada, Mamoru NarukawaClinical Pharmacology and Therapeutics|June 30, 2026
Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory ReviewHiromi Sugano, Mamoru NarukawaDrug Discovery Today|March 7, 2016
Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and JapanManabu Murakami, Mamoru NarukawaTherapeutic Innovation & Regulatory Science|October 3, 2023
Impact of the US Accelerated Approval for New Anticancer Drugs on Time to Verification of Benefit and Regulatory Approval in the EU and JapanAkira Ito, Mamoru NarukawaInternational Journal of Technology Assessment in Health Care|December 22, 2021
Medicine characteristics affecting the time to guidance publication by National Institute for Health and Care Excellence in the single technology appraisal processShunsuke Takada, Mamoru NarukawaTherapeutic Innovation & Regulatory Science|September 22, 2018
Consideration of Factors Affecting the Safety Index in Early Clinical Drug DevelopmentMakoto Kayama, Mamoru NarukawaBMC Cancer|March 16, 2022
Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trialYoshihiro Oda, Mamoru NarukawaBiological & Pharmaceutical Bulletin|October 6, 2024
Safety Evaluation and Information Provision for Appropriate Drug Usage in Elderly Patients in JapanMakoto Onohara, Mamoru NarukawaTherapeutic Innovation & Regulatory Science|January 4, 2024
Characteristics of Anticancer Drugs Approved Under the Accelerated Approval Program in the US: Success or Failure in Converting to Regular ApprovalYoshihiro Oda, Mamoru NarukawaPageof 12